Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | AGXT | P21549 | 2/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2037665 | 0.89 | KLK8 (0.36) | LMNAPTK2 | |
| SCHEMBL7043203 | 0.83 | PTK2 (0.39) | LMNAMAOBPTK2 | |
| SCHEMBL8958940 | 0.81 | AGXT (0.40) | GAAIDO1AGXTLMNATAAR1 | |
| SCHEMBL13624524 | 0.81 | SMN1; SMN2 (0.44) | TAAR1 | |
| SCHEMBL1489170 | 0.80 | NPY5R (0.45) | IDO1AGXTLMNAPTK2 | |
| SCHEMBL5870639 | 0.79 | ALDH1A1 (0.40) | GAAIDO1AGXTTAAR1 | |
| SCHEMBL914693 | 0.79 | FDPS (0.41) | LOXL2MAOB | |
| SCHEMBL4266251 | 0.79 | TRPA1 (0.36) | PTK2 | |
| SCHEMBL22762193 | 0.79 | PPARG (0.38) | PTK2 | |
| SCHEMBL22750793 | 0.79 | PTK2 (0.34) | PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5500417-A | ANTIARTHRITIC | THE UPJOHN COMPANY (US) | 1996-03-19 | — | — | US | claimed |
| EP-0661978-A1 | ARYLMETHYLPHOSPHONATES AND PHOSPHONIC ACIDS USEFUL AS ANTI-INFLAMMATORY AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1995-07-12 | — | — | EP | claimed |
| WO-1994007501-A1 | ARYLMETHYLPHOSPHONATES AND PHOSPHONIC ACIDS USEFUL AS ANTI-INFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1994-04-14 | — | — | WO | claimed |
| US-10777850-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-09-15 | — | — | US | disclosed |
| US-20190051941-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-02-14 | — | — | US | disclosed |
| US-10177414-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-3051618-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME | MITSUBISHI CHEM CORP (JP) | 2018-11-14 | — | — | EP | disclosed |
| EP-3098893-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY USING SAME | MITSUBISHI CHEM CORP (JP) | 2017-11-29 | — | — | EP | disclosed |
| EP-3098893-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND NON-AQUEOUS ELECTROLYTE SOLUTION SECONDARY BATTERY USING SAME | Mitsubishi Chemical Corporation (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-20160322669-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-11-03 | — | — | US | disclosed |
| US-9461334-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-10-04 | — | — | US | disclosed |
| US-20120101065-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120083470-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-8067395-B2 | Inhibitors of tyrosine kinases and uses thereof | PHARMACYCLICS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100035841-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7625880-B2 | Inhibitors of tyrosine kinases and uses thereof | PHARMACYCLICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1981888-A2 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | Pharmacyclics, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080039426-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| WO-2007087068-A2 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006086609-A2 | INHIBITORS OF TRYPTASE | AXYS PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035841-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | GAA 413/4885IDO1 1595/4885AGXT 1509/4885 |
| US-20120083470-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | GAA 413/4885IDO1 1595/4885AGXT 1509/4885 |
| US-20080039426-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | GAA 413/4885IDO1 1595/4885AGXT 1509/4885 |
| US-20120101065-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | GAA 413/4885IDO1 1595/4885AGXT 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.